Pharmaceutical Technology

AUGUST 18, 2023

Coeptis Therapeutics has exclusively licensed allogeneic immuno-oncology platform and clinical stage assets from Deverra Therapeutics.

52

52

Pharmaceutical Technology

MAY 25, 2023

Pyxis Oncology has made a definitive agreement to buy biopharmaceutical company Apexigen, in a deal valued at nearly $16m. Pyxis Oncology will issue 0.1725 shares of its common stock, with par value of $0.001 per share, for each Apexigen share.

Immunization 52

Immunization 52

pharmaphorum

JUNE 28, 2022

For Astellas, the alliance takes the spotlight off the current travails with its gene therapy programmes, with an FDA clinical hold imposed on another candidate – for Pompe disease – in the last few days. The post Astellas pumps $90m into Sutro immuno-oncology alliance appeared first on.

Immunization 105

Immunization FDA 105

Pharmafile

JANUARY 5, 2023

Summary: Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Published date: 05/01/2023. read more.

52

52

Pharmaceutical Technology

JULY 13, 2022

The initial agreement was signed in February 2020 for discovering, developing and marketing new immuno-oncology therapies based on Bicycle’s bicyclic peptide technology. The agreement is exclusive of the compounds in the oncology pipeline of Bicycle, including its immuno-oncology candidates.

Compounding 59

Compounding 59

Pharmaceutical Technology

DECEMBER 19, 2022

Sanofi has extended the partnership with Innate Pharma for natural killer (NK) cell therapeutics in oncology. Innate is also eligible to receive a total of up to $1.43bn (€1.35bn) in preclinical, clinical, regulatory and commercial milestone payments and royalty payments on net sales in the future.

105

105

pharmaphorum

JUNE 1, 2022

Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two glycoprotein targets. The Japanese drugmaker is paying $20.5

98

98

pharmaphorum

APRIL 8, 2022

billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. It was launched as Intron A by Schering-Plough (now Merck & Co) in the 1980s before being discontinued by the company in 2019 based on evaluation of its clinical activity and the emergence of alternative therapies.

Immunization 105

Immunization 105

Pharma Mirror

OCTOBER 22, 2021

ADELAIDE, AUS, Oct 19, 2021 – (ACN Newswire) – Agilex Biolabs, the Australian regulated bioanalytical and toxicology laboratory facilities for clinical trials is presenting a new webinar entitled “Getting it right! Agilex Biolabs’ Director, Immunoassay, Kurt J. Sales (B.Sc; B.Sc (MED) Hons; M.Sc, Ph.D,

Vaccines 52

Vaccines 52

Pharmaceutical Technology

APRIL 10, 2023

Aviceda’s HALOS (high-affinity ligands of sigelcs) nanotechnology platform leverages glycobiology to modulate the innate immune system to develop advanced breakthrough therapeutics, focusing on immuno-oncology. Aviceda Glycotech has been created as an oncology-focused spin-off company from Aviceda Therapeutics and Queen’s.

Immunization 103

Immunization 103

pharmaphorum

JULY 23, 2021

If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows no signs of slowing down. The post Digital tools key to immuno-oncology’s future: report appeared first on.

52

52

pharmaphorum

NOVEMBER 17, 2020

Are you interested in finding the next breakthrough in immuno-oncology preclinical or clinical development? Recent scientific, clinical breakthroughs and high-profile industry deals have reignited the race to find the next blockbuster TGF-ß inhibitor for immuno-oncology applications.

52

52

pharmaphorum

JULY 8, 2021

GlaxoSmithKline’s head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. . billion acquisition of Tesaro, which added PARP inhibitor Zejula (niraparib) and a pipeline of other oncology candidates.

Compounding 105

Compounding 105

pharmaphorum

NOVEMBER 9, 2021

Once widely acknowledged as so special that only scientists and clinical specialists need to apply, oncology has become exponentially more clinically targeted and sophisticated over the last decade. Yet how many other therapy areas have market leaders that don’t even have clinical approved indication in that indication?

Cerner 98

Cerner 98

pharmaphorum

OCTOBER 17, 2022

Their success led to the discovery of an entirely new principle for cancer therapy – the field of immuno-oncology – one that is now a mainstay of cancer treatment, changing the way these diseases can be managed. Marie-Louise Fjällskog has over 30 years of experience in clinical oncology, translational research, and drug development.

Immunization 115

Immunization 115

Pharmaceutical Technology

SEPTEMBER 8, 2022

On concluding the deal, the Good Therapeutics team intends to leverage its technology to design conditionally active therapies for other immuno-oncology targets and further in a new firm, Bonum Therapeutics.

Immunization 111

Immunization 111

pharmaphorum

MARCH 2, 2022

million upfront to kick off the collaboration, which will see Adagene’s SAFEbody technology applied to monoclonal and bispecific antibodies for a range of immuno-oncology applications. The French drugmaker is paying $17.5 Another $2.5 billion is in the offing in future milestone payments. That followed last year’s $3.2

Immunization 52

Immunization 52

Pharmaceutical Technology

JUNE 19, 2023

Coherus BioSciences has signed a definitive merger agreement to buy clinical-stage immuno-oncology (I-O) company Surface Oncology, in a deal valued at $65m. Coherus BioSciences will gain access to Surface Oncology’s two differentiated clinical stage assets, SRF388 and SFR114.

Immunization 52

Immunization FDA 52

Pharmafile

APRIL 13, 2023

Crescendo is a UK-based, clinical stage immuno-oncology company with an extensive proprietary pipeline of novel, targeted T cell enhancing Humabody® therapeutics. read more

40

40

Pharmaceutical Technology

OCTOBER 14, 2022

It is currently being assessed in combination with Merck’s anti-PD-1 therapy, Keytruda, as an adjuvant treatment for high-risk melanoma patients in a Phase II clinical trial being conducted by Moderna.

Vaccines 115

Vaccines Research Laboratories Immunization 115

pharmaphorum

OCTOBER 26, 2022

The stream of novel targets will leverage the proprietary discovery platforms of Normunity’s scientific founder Dr Lieping Chen, an immuno-oncologist who was one among other contributors within the field to identify PD-L1 (B7-H1). The emerging targets will be interrogated and validated together pre-clinically and clinically.

Immunization 52

Immunization 52

European Pharmaceutical Review

FEBRUARY 7, 2023

MSD (Merck & Co) and Nectin Therapeutics have agreed to enter into a clinical trial collaboration, to investigate anti-PVR monoclonal antibody NTX1088 in combination with KEYTRUDA ® (pembrolizumab). The Phase I , open label clinical trial was initiated in November 2022.

Immunization 52

Immunization Labelling 52

European Pharmaceutical Review

MAY 4, 2023

Martin Vogel, Janssen’s Therapeutic Area Lead Oncology for the Europe, Middle-East and Africa (EMEA) region shared with EPR what makes the BsMAb promising for treating this indication. Clinical Lung Cancer. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. 2022; 24(2): 89 – 97.

Immunization 96

Immunization Chemotherapy FDA 96

pharmaphorum

APRIL 20, 2022

per-share deal values CheckMate at around $250 million, and revolves around the toll-like receptor-9 (TKR9) agonist, which is in clinical testing in combination with other drugs for melanoma and non-melanoma skin cancers, as well as head and neck cancer. The post Regeneron seeks CheckMate in immuno-oncology play appeared first on.

Immunization 52

Immunization FDA 52

Pharmafile

APRIL 18, 2023

Published date: 18/04/2023 Summary: NOUS-PEV demonstrated good safety and immunogenicity, and induced durable neoantigen-specific T cell responses that were detected for over 6 months and increased T cell infiltration in tumors demonstrating positive anti-tumor activity in solid tumors BASEL, Switzerland – 18th April 2023 - Nouscom, a clinical stage (..)

40

40

Pharmaceutical Technology

MAY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Oncolytic viral proteins. Rubius Therapeutics and Pathovax are in second and third positions, respectively.

Adverse Reactions 52

Adverse Reactions Mayo Clinic Pharmaceutical Companies Pharmaceutical Companies 52

European Pharmaceutical Review

FEBRUARY 15, 2023

The results suggest “that neoadjuvant nivolumab was safe in long-term follow-up,” commented Patrick Forde, MBBCh, an Associate Professor of oncology and Director of the Thoracic Oncology Clinical Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Chemotherapy 93

Chemotherapy Immunization FDA 93

PharmaShots

MAY 14, 2023

Shots: LaNova Medicines will receive an up front and near-term fees of ~$55M and is eligible to receive additional development and commercial milestones of ~$545M along with royalties on net sales globally AstraZeneca to get an exclusive license globally to research, develop, and commercialize LM-305, a pre-clinical stage ADC targeting G protein-coupled (..)

40

40

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Microbio t a restoration therapy. By means of geographic reach, the Spanish National Research Council holds the top position.

Hospitals 98

Hospitals Pharmaceutical Companies Pharmaceutical Companies 98

Pharmaceutical Technology

APRIL 14, 2023

This will speed up the discovery stage and accelerate the timeline for the clinic. Twist CAR and TCR Libraries allow researchers and drug developers to fine-tune these receptors to address the challenges of cell therapies, including off-target toxicity, enabling rapid advancement toward the clinic.”

98

98

pharmaphorum

JULY 20, 2021

Gilead Sciences just forged even closer ties with its cancer drug partner Arcus Biosciences, enticing the biotech’s chief medical officer Bill Grossman to a new role as its head of oncology clinical research. Bill Grossman.

52

52

Pharmaceutical Technology

NOVEMBER 18, 2022

Regeneron Bispecifics head and Immuno-oncology senior vice-president John Lin said: “At Regeneron, we're focused on developing a paradigm-changing portfolio of oncology medicines for patients by combining a deep understanding of cancer biology with cutting-edge technologies.

52

52

Pharmaceutical Technology

JUNE 6, 2023

According to Globaldata, it is involved in 1 clinical trial, which is ongoing. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Buy the model here. MRNA-0184 Overview mRNA-0184 is under development for the treatment decompensated heart failure.

Vaccines 40

Vaccines 40

Pharmaceutical Technology

JUNE 12, 2023

Astellas Pharma executive director and immuno-oncology development interim head Pranob Bhattacharya stated: “Gastric cancer remains the third deadliest cancer in Japan, leading to approximately 50,000 deaths per year despite significant strides to reduce the impact of this cancer. Zolbetuximab is an investigational Claudin 18.2

Chemotherapy 52

Chemotherapy 52

pharmaphorum

DECEMBER 14, 2021

Pfizer’s bid comes just weeks after it agreed a smaller bolt-on deal to buy immuno-oncology specialist Trillium Therapeutics for $2.3 Eyebrows have been raised about the timing of the offer, just ahead of that readout, but Pfizer may be looking to lock in the deal early given interest in Arena among other big pharma companies.

Compounding 98

Compounding Vaccines FDA 98

pharmaphorum

APRIL 26, 2022

Ben Hargreaves speaks to companies that are developing therapies not just in gastrointestinal conditions but also in broader areas, such an immuno-oncology. The treatment has been granted US FDA breakthrough therapy designation and orphan drug designation, and has also completed a phase 3 clinical study. Compelling advantages.

Immunization 115

Immunization FDA 115

Pharmaceutical Technology

MAY 24, 2023

CohBar has entered into a definitive merger deal with Morphogenesis to advance a late-stage clinical immuno-oncology pipeline of therapies to overcome resistance to cancer immunotherapy.

Vaccines 52

Vaccines Immunization 52